Initiator Pharma A/S (STO:INIT)

Sweden · Delayed Price · Currency is SEK

3.350

+0.110 (3.40%)

Apr 29, 2026, 4:35 PM CET

-48.93% (1Y)

Market Cap	221.79M
Revenue (ttm)	n/a
Net Income (ttm)	-19.83M
Shares Out	68.45M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	366,174
Average Volume	167,611
Open	3.250
Previous Close	3.240
Day's Range	3.220 - 3.450
52-Week Range	2.560 - 6.600
Beta	0.07
RSI	53.40
Earnings Date	May 8, 2026

About Initiator Pharma

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to treat neuropathic pain; and IP2018, a monoamine reuptake inhibitor which completed Phase IIa for the treatment of psychogenic erectile dysfunction. The ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Employees 1

Stock Exchange Nasdaq Stockholm

Ticker Symbol INIT

Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

Initiator Pharma Transcript: Stora Aktiedagarna 2026

Pudafensine, a novel monoamine modulator, is advancing in clinical trials for ED and vulvodynia, targeting large unmet needs with strong safety and efficacy data. The company is well-funded through 2027, focusing on partnerships and expects key clinical and business milestones within the next 12-14 months.

6 weeks ago - Transcripts

Initiator Pharma Transcript: DNB Carnegie Healthcare Seminar 2026

Pudafensine is advancing in late-stage clinical trials for both erectile dysfunction and vulvodynia, targeting large unmet needs with a unique dual mechanism and strong safety profile. Partnering discussions are intensifying, with key data readouts expected by year-end 2024.

7 weeks ago - Transcripts

Initiator Pharma Transcript: Life Science Summit 2025

A novel drug targeting monoamines is advancing through clinical trials for vulvodynia, a large unmet need in women's health, with a first-in-class approach and strong safety profile. The program is well-financed, with a pivotal trial underway and significant market potential projected.

5 months ago - Transcripts

Initiator Pharma Transcript: Investing in Life Science 2025

Pudafensine, a CNS-acting candidate, has shown efficacy and safety in sexual dysfunction and pain, with a Phase II vulvodynia trial set to start in the UK by late 2025. Strong financial backing and strategic partnerships support expansion into high-need markets.

7 months ago - Transcripts